Mao Mei

Star

Rubus parvifolius L.

Not yet clinically reviewed

Family: Rosaceae Genus: Rubus Species: parvifolius Pinyin: Mao Mei

Synonyms: Rubus triphyllus Thunb.

Japanese raspberrysmall-leaf bramble茅莓

Traditionally used for

  • Bowel health
  • Urinary & fluids
  • Pain & joints
  • Skin
  • Liver & jaundice

Cautions & contraindications

  • Pregnancy
Moderate evidence · 4 studies

☯ TCM Properties

Category: regulating blood
Temperature: neutral
Taste: sweet, sour
Meridians: liver, kidney
Functions:

Dissipates Blood Stasis, removes toxicity, kills parasites and alleviates pain

Traditional Chinese Uses

Mao Mei (Herba Rubi Parvifolii) is the root, stem or whole plant of Rubus parvifolius, a folk medicinal of southern and eastern China. Sweet and sour in flavour and neutral in nature, it is used to invigorate and cool the Blood, dissipate Blood Stasis, clear Heat and resolve toxicity, disperse accumulations, promote urination and reduce swelling, and to relieve pain. Its tannin-rich tissues also give it an astringent, bleeding- and diarrhoea-checking action.

Traditional indications include enteritis and dysentery, jaundice and chronic hepatitis, hepatosplenomegaly, urinary tract infection and stones, rheumatic bone pain, and traumatic contusions with swelling and pain, for which it may be decocted internally or applied topically for sores and eczema. It is a country remedy rather than a mainstream classical herb, so it appears more in folk and regional practice than in the major materia medica formulas.

Western Herbalism Properties

Actions:
astringent

Click a node for details · double-click to expand it · Ctrl/⌘ + scroll or two fingers to zoom and pan.

Loading graph…

Botanical Description

Mao Mei (茅莓), source of Herba/Radix Rubi Parvifolii, is Rubus parvifolius L. (Rosaceae), a scrambling deciduous shrub 0.5-2 m tall common on sunny hillsides, thickets, and roadside waste across China, Japan, Korea, and eastern Asia. The arching prickly stems bear pinnately compound leaves of three to five broadly rhombic, white-tomentose, doubly serrate leaflets. Small pink to rose five-petalled flowers form loose corymbs, ripening into hemispherical red aggregate fruits of juicy drupelets. The whole plant or root is used as the drug. Bitter, astringent, and cool, it dispels blood stasis, resolves toxicity, kills parasites, and relieves pain, used for traumatic injury, rheumatic pain, dysentery, hepatitis, and bleeding. It should not be confused with Mei/Wu Mei, the fruit of Prunus mume.

Habitat:

Sunny hillsides, scrub thickets, forest margins, roadsides, and waste ground at low to middle elevations.

Native Region: China, Japan, Korea, Taiwan

Active Constituents

Ursolic acid

Ursane-type pentacyclic triterpenoid

Concentration: reported from the root; not quantified in the standard drug

The most cited triterpenoid of the species and a candidate active. Its practical limitation is pharmacokinetic: oral bioavailability in rodents is roughly 1-3%, and most of the efficacy work that uses it was done by intraperitoneal injection rather than by the oral route a decoction takes.

Nigaichigoside F1

Triterpenoid saponin

Concentration: reported from the root; not quantified in the standard drug

One of the saponins carried in the total saponin fraction (TSRP) that most of the species-specific pharmacology uses, and a marker cited in the anti-fatigue work.

Suavissimoside R1

Triterpenoid saponin

Concentration: reported from the root; not quantified in the standard drug

A candidate active metabolite supported by bioactivity-guided fractionation in this species rather than inferred from other Rubus species.

Sanguiin H-6

Ellagitannin

Concentration: reported from the plant; not quantified in the standard drug

A dimeric ellagitannin common in Rosaceae and among the candidate actives flagged for this species. Ellagitannins of this size are poorly absorbed intact and are largely metabolised by gut flora.

Quercetin 3,7-diglucoside

Flavonol glycoside

Concentration: 12.73 mg/g dry weight of the leaf extract

The single most abundant quantified compound in the leaf, in an extract that suppressed IL-6, IL-8 and MCP-1 in TNF-alpha/IFN-gamma-stimulated HaCaT keratinocytes. Note that this quantification is for the leaf; the drug used in Chinese practice is usually the whole herb or root.

Hirsutrin (quercetin 3-O-glucoside)

Flavonol glycoside

Concentration: 4.74 mg/g dry weight of the leaf extract

The second most abundant leaf flavonoid quantified, contributing to the extract's anti-inflammatory profile in the keratinocyte model.

Ellagic acid

Ellagitannin-derived phenolic

Concentration: 1.58 mg/g dry weight of the leaf extract; also reported from root and fruit

Present across root, fruit and leaf and responsible for part of the antioxidant activity attributed to the plant.

Kaempferol 3-O-glucuronide

Flavonol glycoside

Concentration: 0.31 mg/g dry weight of the leaf extract

A minor quantified leaf flavonoid in the same profile.

Parvifolactone A and rubuside P

Oleanane-type triterpenoids

Concentration: isolated from the roots; not quantified

Two new oleananes described from the roots alongside eleven known triterpenoids including fupenzic acid, euscaphic acid and maslinic acid. No pharmacology has been published for the two new compounds themselves.

4-Hydroxy-3-methoxystyrene

Volatile phenylpropanoid

Concentration: reported as about 66% of the leaf volatile oil

The dominant component of the leaf volatile oil, to which the broad-spectrum in vitro antibacterial activity of that oil is attributed. It is not a component of a water decoction of the root.

⚠ Drug Interactions

Warfarin, direct oral anticoagulants and antiplatelet drugs

Theoretical Evidence: Theoretical

Mao Mei is classified as a stasis-dissipating, blood-moving herb, which is often taken to imply an antiplatelet or anticoagulant effect. For this species that inference is unsupported: the 2026 review found no coagulation or platelet pharmacology for R. parvifolius, and no published pharmacokinetic data for any candidate marker after oral dosing. The honest position is that the interaction can neither be predicted nor excluded.

Clinical note: If a patient on anticoagulation takes Mao Mei, monitor INR or anti-Xa as you would for any new unstudied botanical rather than assuming a class effect.

Use in pregnancy alongside any medication

Theoretical Evidence: Theoretical

The Guangdong Provincial Standard for Chinese Medicinal Materials (2019) carries a pregnancy contraindication for this drug, based on traditional experience rather than study data. The 2026 review is explicit that no subchronic, chronic, genotoxicity, reproductive or developmental toxicity studies have been published for R. parvifolius; the only toxicity data are acute, with total saponins tolerated to 3.0 g/kg intraperitoneally and 10 g/kg intragastrically in mice.

Clinical note: Observe the contraindication in pregnancy. Do not present the absence of toxicity studies as reassurance.

Fu Pen Zi (Rubus chingii unripe fruit) and Rubus coreanus (bogbunja)

Theoretical Evidence: Theoretical

Most of the Rubus phytochemistry and pharmacology in circulation is for R. chingii or R. coreanus, not for R. parvifolius. Fu Pen Zi is the unripe fruit of R. chingii, a warm kidney-supplementing astringent used for enuresis and seminal emission; Mao Mei is the whole herb or root of R. parvifolius, a cooling stasis-dissipating and toxin-resolving drug. Data on one should not be read across to the other, and the species should not be substituted in dispensing.

Clinical note: Check the binomial and the plant part on the label. Root or whole herb of R. parvifolius is the drug; fruit of another Rubus is not.

Evidence Tier

Moderate evidence · 4 studies

Recorded studies by study design, strongest design at the top. This is a study-design tier only, not a GRADE rating: it does not weigh risk of bias, consistency or precision.

Verified: design read from PubMed for a DOI that resolves to the cited paper Unverified: taken from the study's recorded description

Clinical Studies

Total Saponins of Rubus Parvifolius L. Exhibited Anti-Leukemia Effect in vivo through STAT3 and eIF4E Signaling Pathways

Xu XF, Cheng RB, Zhang XJ, Gao RL (2018) Chinese Journal of Integrative Medicine animal

K562 chronic myeloid leukaemia xenografts in nude mice were treated with total saponins of R. parvifolius at 20, 40 and 100 mg/kg against a vehicle and a cytarabine control. Tumour growth rate and weight fell significantly, HE and TUNEL staining showed apoptosis, bcl-2 was downregulated, and phosphorylation of eIF4E and STAT3 decreased.

Total saponins in Rubus parvifolius L. induce lymphoma cells apoptosis through upregulated Bax/Fas and downregulated Bcl-2 in vivo and in vitro

Xu XF, Cheng RB, Zhang XJ, Gao RL (2019) Traditional Medicine Research animal

From the same group as the leukaemia work, reporting apoptosis induction in lymphoma cells with upregulated Bax and Fas and downregulated Bcl-2 both in cell culture and in vivo. The journal is a low-visibility one and the finding has not been independently replicated.

Total saponins from Rubus parvifolius L. inhibits cell proliferation, migration and invasion of malignant melanoma in vitro and in vivo

Cao J, Zhao X, Ma Y, Yang J, Li F (2021) Bioscience Reports animal

Total saponins inhibited proliferation, invasion and migration of human A375 melanoma cells in vitro, and in sixty A375 xenograft nude mice, 25, 50 and 100 mg/kg for fourteen days blocked tumour growth against vehicle with cyclophosphamide as comparator. Lung metastasis after tail-vein injection of A375 cells was also reduced.

Phytochemical Profiling and Anti-Inflammatory Activity of Rubus parvifolius Leaf Extract in an Atopic Dermatitis Model

Kim J, Kakooza D, Lee CD, Jung SY, Choi K, Moon SK, Kim H, Lee S (2025) Life in vitro

Quantified five leaf flavonoids and phenolics totalling 19.36 mg/g, led by quercetin 3,7-diglucoside at 12.73 mg/g and hirsutrin at 4.74 mg/g. In TNF-alpha and IFN-gamma-stimulated HaCaT keratinocytes the extract dose-dependently suppressed IL-6, IL-8 and chemokine expression, with 73.0% inhibition of MCP-1 at 100 ug/mL.

Historical Texts

Ben Cao Shi Yi (Supplement to the Materia Medica)

Tang dynasty, 739 CE
The earliest materia medica source cited for Mao Mei, from which the drug descends into regional southern practice rather than the mainstream Han and Ming canon.

Quan Guo Zhong Cao Yao Hui Bian (National Compendium of Chinese Herbal Medicine)

Modern, 1975
Records the traditional actions of clearing heat and resolving toxicity, activating the blood and resolving stasis, stopping bleeding, and relieving pain and swelling, with a traditional dose of 6-15 g of dried root by decoction.

Guangdong Provincial Standard for Chinese Medicinal Materials

Modern, 2019
The current provincial standard covering this drug. It carries a pregnancy contraindication based on traditional experience; no reproductive toxicity study underlies it.

References

  1. Duan B, Zhang C, Hu X, Bai X, Peng H, Zhao H. Ethnopharmacology, phytochemistry, and pharmacology of Rubus parvifolius L (Máoméi): evidence and translational challenges . Frontiers in Pharmacology (2026) [DOI]
  2. Choi JS, Son BW, Do JC. Triterpenoids from the roots of Rubus parvifolius . Archives of Pharmacal Research (1991) [DOI]

This information is for educational purposes only and is not intended to replace professional medical advice. Always consult a qualified healthcare provider before using any herbal remedy, especially if you are pregnant, nursing, or taking medications.

📝 Notes

Public notes from the community and your own private notes on Mao Mei.

No notes yet.

Log in or register to add your own notes.

Back to Herb Database